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Synthesis and biological activity of oxazolopyrimidines  
Laurens M. De Coen,[a] Bart I. Roman,[a,b] Marine Movsisyan,[a] Thomas S. A. Heugebaert [a]  and 
Christian V. Stevens*[a] 
 
Abstract: In this work, the synthesis of oxazolo[4,5-d]pyrimidines and 
oxazolo[5,4-d]pyrimidines is reviewed. The review is focused on the 
construction of the scaffold, rather than on further modification. 
Nevertheless, selected examples illustrate some of the most common 
modifications of these scaffolds. The synthetic part is complemented 
by an overview of their biological activity. This review covers literature 
and patents from 1967 until present. 
1. Introduction 
The oxazolopyrimidine scaffold is a nucleobase isostere of 
frequent use in medicinal chemistry. This pharmacophore is 
present in a range of receptor modulators, enzyme inhibitors and 
nucleoside analogs. Relevant clinical settings are predominantly 
situated in oncology and infectious diseases. Oxazolopyrimidines 
are the subject of a significant body of literature, including an 
important number of recent patent applications by both 
pharmaceutical corporations and academic groups. 
 
Given this significance, a comprehensive overview of the 
synthetic routes towards the different classes of 
oxazolopyrimidines would be of great interest to the field. This 
work summarizes the available methodology to construct 
oxazolo[4,5-d]pyrimidines and oxazolo[5,4-d]pyrimidines, as 
published in primary scientific literature and patents up to the end 
of 2017. Oxazolo[5,4-d]pyrimidines constitute a well explored 
chemical family and cover most of this overview. In contrast, the 
oxazolo[4,5-d]pyrimidine scaffold has been underexplored. The 
main focus of this review is on oxazolopyrimidine scaffold 
construction rather than further derivatization. Selected examples 
will however illustrate some of the most common modifications.  
 
The synthetic part is complemented by an overview of the 
biological activity of relevant structures in (pre)clinical 
development. For each of these structures the assembly of the 
oxazolopyrimidine moiety was accomplished using methodology 
covered in this work.  
 
Laurens De Coen was born in Ghent, 
Belgium (1987) and obtained a Master 
degree in Bioscience Engineering (Chemistry 
and Bioprocess Technology) at Ghent 
University (Belgium). He performed research 
on zingerone derivatives and related 
chalcones as anticancer compounds under 
the supervision of Prof. Dr. ir. C. V. Stevens 
in 2011. Subsequently, he joined a Ph.D. 
project on medicinal scaffolds with Prof. C. V. 
Stevens as promoter. His research interests 
include heterocyclic chemistry – mainly 
furans, thiophenes, pyrroles, and oxazoles– with medicinal relevance. 
Bart I. Roman (Kortrijk, 1984) obtained his 
M.Sc. in Chemical Engineering in 2006 and a 
Ph.D. in Applied Biological Sciences: 
Chemistry in 2012 (with Christian Stevens, 
Ghent University, Belgium). In 2014, he 
conducted a postdoctoral stay at the lab of 
Phil Baran (the Scripps Research Institute). 
He is currently working as a postdoctoral 
associate in the SynBioC research group at 
Ghent University. Bart’s research interests lie 
in the discovery of innovative (bio)chemical 
technology to interrogate, understand and 
pharmacologically modulate the cellular and 
molecular events driving malignant and neglected diseases. His work 
encompasses QSAR methodology, drug design, organic synthesis and 
natural products chemistry. 
Marine Movsisyan (Armenia, 1990) was 
granted a Master’s degree in Bioscience 
Engineering at Ghent University, Belgium, in 
2013. She subsequently joined the SynBioC 
research group to pursue a PhD degree 
under the guidance of Prof. Christian V. 
Stevens at the Department of Sustainable 
Organic Chemistry and Technology. Her 
research interests lie in the synthesis of 
building blocks using continuous flow 
technology in collaboration with industry. 
[a] L.M., De Coen; B.I., Roman; M., Movsisyan; C.V., Stevens 
Department of Green Chemistry 
Faculty of Bioscience Engineering, Ghent University 
Coupure Links 653, 9000 Ghent 
E-mail: Chris.Stevens@UGent.be 
[b] B.I., Roman 
Cancer Research Institute Ghent (CRIG) 
De Pintelaan 185, 9000 Ghent 
 
 
 
 
 
 
 
 
10.1002/ejoc.201800133
Ac
ce
pt
ed
 M
an
us
cr
ip
t
European Journal of Organic Chemistry
This article is protected by copyright. All rights reserved.
MICROREVIEW          
 
 
 
 
 
Thomas Heugebaert (1984) obtained his 
degree in Bioscience Engineering in 2007 
from Ghent University, Belgium. There, he 
joined the Department of Sustainable 
Organic Chemistry and Technology, 
research group SynBioc, under the guidance 
of Prof. Christian Stevens. He obtained his 
Ph. D. in 2012, studying gold catalysis and its 
application in the synthesis of biologically 
active organic molecules, including plant 
hormones, azaheterocyclic analgesics and 
five-membered heteroaromatic compounds. 
His current postdoctoral research focuses on the development of 
microreactor technology, improving its efficiency for gas/liquid interface 
photochemistry. His postdoctoral stay at Graz University, Austria, in 2014, 
under the guidance of Prof. Oliver Kappe, has shown the efficient application 
of continuous flow photochemistry, in the field of clean oxidation technology 
and renewable chemicals. 
Prof. Dr. Ir. Christian V. Stevens (1965) is 
senior full professor at the Department of 
Green Chemistry and Technology at the 
Faculty of Bioscience Engineering (Ghent 
University, Belgium). He graduated in 1988 
and obtained a PhD in 1992 working with 
Prof. N. De Kimpe at Ghent University. He 
then performed post-doctoral work at the 
University of Florida guided by Prof. Alan 
Katritzky in 1992−1993 as a NATO Research 
Fellow. In 2000, he became associate 
professor and full professor in 2008. Chris 
has published over 270 international peer reviewed papers and 14 patents 
and received several prizes. His research interest focuses on synthetic 
heterocyclic chemistry, the use of flow chemistry and the chemical  
modification of renewable resources for the industry. He is a Fellow of the 
Royal Society of Chemistry Britain and member of the American Chemical 
Society. 
2. Synthesis and biological activity of 
oxazolo[4,5-d]pyrimidines  
Oxazolo[4,5-d]pyrimidines have been investigated to a limited 
extent only. One reason is the lack of a versatile building block 
such as 5,7-dichlorooxazolo[4,5-d]pyrimidine. Scaffold 
construction is generally achieved by oxazole ring annulation on 
a functionalized pyrimidine or by pyrimidine ring annulation on a 
functionalized oxazole. 
2.1. Scaffold construction starting from a functionalized 
pyrimidine 
Oxazolo[4,5-d]pyrimidines can be synthesized starting from a 4-
amino-5-hydroxypyrimidine by annulation of an oxazole ring 
(Scheme 1). The carbon source for the C(2) of the scaffold can 
be an ester, orthoester, thioimidate, carboxylic acid or formamide.  
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Scheme 1.  Oxazolo[4,5-d]pyrimidines by annulation of oxazole rings.  
Kato et al. were the first to report the synthesis of oxazolo[4,5-
d]pyrimidines. They discovered that the reaction of 2,4-diamino-
5-hydroxy-6-methylpyrimidine 7 with phenyl esters delivered 
hemi-aminals 8, which were isolated as stable compounds at 
room temperature in moderate yields (Scheme 2). When these 
hemi-aminals were heated to 110-140 °C, ring closure to the 
oxazolopyrimidines 10 was observed, but also ring opening to the 
ester and the amide. To reduce these side reactions, the hemi-
aminals were first methylated with iodomethane and then heated. 
The desired oxazolo[4,5-d]pyrimidines 10 were still only obtained 
in low yields.[1,2]  
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Scheme 2. Reaction of 2,4-diamino-5-hydroxy-6-methylpyrimidine with 
phenyl esters as reported by Kato et al. [1,2] 
A more direct approach was developed by Doise and coworkers. 
They obtained the desired scaffold in one step by condensing 
aminopyrimidinol 3 with excess orthoester and a catalytic amount 
of para-toluenesulfonic acid at high temperature (Scheme 3).[3] In 
later work, a thiobenzyl imidate proved a suitable alternative to an 
orthoester. This lead to an open intermediate 11, which was ring 
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closed by heating at 250 °C for two minutes (Scheme 3). No yields 
were reported for the latter approach.[4]  
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Scheme 3. Condensation of an aminopyrimidinol with excess orthoester 
or a thiobenzyl imidate as reported by Doise and coworkers.[3,4] 
Besides thioimidates and orthoesters, a carboxylic acid can also 
be used as a source of the C(2) carbon atom of the 
oxazolopyrimidine scaffold. When 4-aminopyrimidin-5-ol 3 was 
reacted with 3-hydroxybenzoic acid under harsh reaction 
conditions, oxazolopyrimidine scaffold 13 was obtained in low 
yield (Scheme 4). Further reaction of the phenolic hydroxyl group 
with n-propylisocyanate afforded carbamate 14.[5]  
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Scheme 4. Condensation of an aminopyrimidinol with a carboxylic acid as 
reported by Koskinen and coworkers.[5] 
Formamide can also be used as the source of the C(2) carbon 
atom. Starting from 5-hydroxyuridine 15, a diazocoupling reaction 
gave diazobenzene derivative 16 in very good yield (Scheme 5). 
Raney nickel-catalyzed hydrogenolysis followed by ring closure 
with formamide and polyphosphate ester as dehydrating agent 
finally delivered the nucleoside analogue 18 in low yield.[6]  
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Scheme 5. Condensation of an aminopyrimidinol with formamide as 
reported by Mizuno and coworkers.[6] 
2.2. Scaffold construction starting from a functionalized 
oxazole 
Oxazolo[4,5-d]pyrimidines have also been synthesized starting 
from a functionalized oxazole by annulation of a pyrimidine ring 
(Scheme 6). 
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Scheme 6. Oxazolo[4,5-d]pyrimidines by annulation of a pyrimidine ring. 
Reaction of 1,3-oxazol-5(4H)-one 23 with various amidines gave 
imidazolones 24 in good yields (Scheme 7). These intermediates 
were converted to the oxazolo[4,5-d]pyrimidin-7(6H)-ones 25 by 
heating in refluxing pyridine. In the case of a phenyl or thiomethyl 
substituent at the 5-position of this scaffold, chlorination with 
phosphorous oxychloride was achieved in good yields. The 
obtained chloropyrimidines 26 were then reacted with thiophenol 
to afford final structures 27 in very good yields. The authors did 
not mention whether they also attempted to react 25c (R = NH2) 
with phosphorous oxychloride.[7] 
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Scheme 7. Condensation of dichloromethylidene 1,3-oxazol-5(4H)-ones 
with amidines as reported by Drach and coworkers.[7] 
The synthesis of twenty-eight new C(2)/C(4)-functionalized 
oxazolo[4,5-d]pyrimidines 30 was reported by Cmiljanovic et al. 
(Scheme 8). Unfortunately, the applied synthetic methods and 
characterization of these compounds was not described in detail. 
The only structures of Scheme 8 which were unambiguously 
reported are the final structures 30. According to the reported 
general reaction scheme, the starting material was 4-
aminooxazole 21 with an ester group at the 5-position and 
optionally a substituent at the 2-position. This oxazole was 
cyclized to afford oxazolo[4,5-d]pyrimidin-5,7(4H,6H)-dione 22. 
Chlorination of this compound then lead to 5,7-dichloropyrimidine 
28, which was subsequently substituted at the 7- and 5-positions 
to obtain the final structures 30.[8] 
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Scheme 8. Annulation of pyrimidines to 1,3-oxazol-5(4H)-ones as reported 
by Wymann and coworkers.[8] 
 
2.3. Scaffold construction by rearrangement of 
isoxazolo[3,4-d]pyrimidines 
Nishigaki and coworkers investigated the photochemical behavior 
of 3-arylisoxazolo[3,4-d]pyrimidines 31 and observed a 
photorearrangement upon irradiation with a 100W high-pressure 
mercury lamp yielding the corresponding 2-aryloxazolo[4,5-
d]pyrimidines 33 in very low yields (Scheme 9). Based on a 
previous mechanistic study on the photorearrangement of 
isoxazoles to oxazoles, which proceeds via an azirine 
intermediate, they assumed that this ring transformation also 
occurs via the initial formation of an azirine intermediate, 32, 
followed by recyclization to 33.[9]  
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Scheme 9. Photochemically induced rearrangement of 3-
arylisoxazolo[3,4-d]pyrimidines as reported by Senga and coworkers.[9] 
2.4. Biological activity  
Compound 14 (Figure 1, Scheme 4) is an inhibitor of fatty acid 
amide hydrolase (FAAH) with an IC50 value of 4.5 µM and also 
inhibits monoglyceride lipase (MGL) by 18% at 100 µM. FAAH 
and MGL are the main enzymes responsible for the hydrolysis of 
the two major endogenous cannabinoids N-
arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-
AG). These cannabinoids activate the cannabinoid receptors CB1 
and CB2, which induces biological effects such as relief of pain 
and anxiety. Thus, inhibitors of FAAH and MGL could have 
anxiolytic and analgesic activity.[5] 
Compounds 30 (Figure 1, Scheme 8) were reported in a large 
study on protein kinase B (PKB) inhibitors. PKB plays a key role 
in multiple cellular processes such as glucose metabolism, 
apoptosis, cell proliferation, transcription and cell migration. A 
PKB screening assay protocol was described in the publication, 
but it is not clear whether these compounds were included in the 
screen, and no biological results are thus available for these 
structures.[8] 
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Figure 1. Oxazolo[4,5-d]pyrimidines of biological interest. 
3. Synthesis and biological activity of 
oxazolo[5,4-d]pyrimidines 
The synthesis of oxazolo[5,4-d]pyrimidines has been described to 
a much larger extent than the aforementioned oxazolo[4,5-
d]pyrimidines. Generally, this scaffold can be constructed starting 
from either a functionalized pyrimidine or oxazole.  
3.1. Scaffold construction starting from a functionalized 
pyrimidine 
3.1.1. Starting from a 5-amino-4(,6)-
(di)hydroxypyrimidine 
Possible building blocks to construct oxazolo[5,4-d]pyrimidines in 
a single step are 5-aminopyrimidines with a hydroxyl group or a 
lactam-type carbonyl group on the 4- and/or 6-position (Scheme 
10). The carbon source for the C(2) of the resulting 
oxazolopyrimidine can originate from an anhydride, nitrile or 
trifluoromethyl moiety.  
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Scheme 10. Oxazolo[5,4-d]pyrimidines by annulation of oxazole rings to 
5-amino-4-hydroxypyrimidines. 
Reaction of acetic, propionic or benzoic anhydride with 5-amino-
4,6-dihydroxypyrimidine 34 afforded oxazolo[5,4-d]pyrimidinones 
35 in moderate yields (Scheme 11). Subsequent chlorination with 
phosphorous oxychloride and reaction with morpholine, piperidine 
or various arylamines gave the final oxazolo[5,4-d]pyrimidines 
43.[10,11] Similarly, when diaminopyrimidinol 36 was heated in 
acetic anhydride, oxazolopyrimidinone 44 was obtained in 
moderate yield.[12] When the 6-hydroxyl group of the substituted 
pyrimidine was replaced by a secondary amino group, oxazole 
ring annulation occurred between the 4-carbonyl group and the 5-
amino group of the pyrimidine ring. Treatment of 
amino(glycosylamino)pyrimidinones 45 with acetic anhydride 
under reflux gave (glycosylamino)oxazolopyrimidines 46 in low 
yield.[13]  
 
As mentioned before, a nitrile or trifluoromethyl moiety can also 
serve as the C(2) carbon source. Reaction of nitrile 47 with 5,6-
diaminopyrimidin-4-ol 40 in hot polyphosphoric acid afforded 7-
aminooxazolo[5,4-d]pyrimidine 48 (Scheme 12). The yield of this 
reaction was not reported.[14] Qiao and coworkers discovered that 
the trifluoromethyl group of structure 49 hydrolyzed to the 
corresponding carboxylic acid quite easily under basic conditions. 
This degradation pathway was used to replace the labile CF3-
group by more stable groups. Reaction of excess of 5,6-
diaminopyrimidin-4-ol 40 with 49 under mild aqueous conditions 
gave the C(2)-substituted 7-aminooxazolo[5,4-d]pyrimidine 50 in 
low yield. Subsequent methylation afforded 7-
methylaminooxazolopyrimidine 51 in low yield.[15] 
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Scheme 11. Condensation of 5-amino-4-hydroxypyrimidines with anhydrides. 
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Scheme 12. Condensation of 5-amino-4-hydroxypyrimidines with nitriles and trifluoromethyl groups. 
3.1.2. Cyclization of a 5-acylamino-4(,6)-
(di)hydroxypyrimidine 
One of the major approaches for the construction of oxazolo[5,4-
d]pyrimidines is the cyclization of a 5-acylaminopyrimidine with a 
hydroxyl group or lactam-type carbonyl group on the 4- and/or 6-
position (Scheme 13). Typical dehydrating agents are 
phosphorous oxychloride and polyphosphoric acid, but other 
reagents or techniques may also be used.  
 
5-Acylaminopyrimidine 73 was treated with excess N,N-
dimethylaniline in phosphorous oxychloride under reflux 
conditions to afford oxazolopyrimidine 74 (Scheme 14). The very 
low yield of product 74b was attributed to side reactions such as 
that of phosphorous oxychloride with the free 4-amino group 
yielding phosphorochloridate compounds.[16] Compound 75, 
which also possesses a 4-amino group, was ring-closed to 
oxazolopyrimidine 76 in moderate yield.[17] Pyrimidines 58 with a 
free 2-amino group were cyclized to 5-amino-7-
chlorooxazolo[5,4-d]pyrimidines 59 in moderate to very good 
yields.[18] 
 
Pyrimidine 60, lacking a free amino group, was cyclized to 7-
chlorooxazolo[5,4-d]pyrimidine 61 in boiling phosphorous 
oxychloride in good yields (Scheme 15). 
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Scheme 13. Oxazolo[5,4-d]pyrimidines by cyclization of 5-acylamino-4-hydroxypyrimidines. 
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Scheme 14. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing excess N,N-dimethylaniline in phosphorous oxychloride. 
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Scheme 15. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing phosphorous oxychloride or phosphorous pentachloride. 
Subsequent reaction with sodium thiosulfide in ethanol afforded 
the oxazolopyrimidine-7-thiones 77 in very good yields.[19] 
Pyrimidine 78 was cyclized to 79 in very good yield under similar 
reaction conditions. Subsequent substitution of the chlorine by 
ammonia afforded 7-aminooxazolopyrimidine 80.[17] Remarkably, 
when dihydroxypyrimidine 81 was cyclized with phosphorous 
pentachloride, oxazolopyrimidine-7(6H)-one 82 was obtained. 
The isolated yield was not mentioned so it is not clear to what 
extent the oxygen at the 7-position was substituted by a chlorine 
atom, if at all. Further alkylation of this compound with 1-
bromopropane afforded 7-propoxy derivative 83 in 18% yield and 
the 6-N-propyl regioisomer in 19% yield.[20]  
 
Reaction of pyrimidine 84 with furyl carbonyl chlorides afforded 
the 4-acylaminopyrimidines 67 in good yields (Scheme 16). 
Subsequent ring closure with phosphorous oxychloride gave 7-
chlorooxazolopyrimidine 68, which then reacted with sodium 
azide to get 7-azidooxazolopyrimidine 85 in excellent yields. 
Reduction of the azide followed by oxidation of the sulfide 
afforded sulfone 87, which was then reacted with various amines 
to give the final 2,5-disubstituted-7-aminooxazolopyrimidine 
88.[21]  
 
In a similar example, polyphosphoric acid (PPA) was used to ring 
close pyrimidine 90 to oxazolopyrimidine 91 (Scheme 17). The 
oxazolopyrimidine-7-ol 91 was subsequently chlorinated by 
phosphorous oxychloride to obtain 7-chlorooxazolopyrimidine 92. 
Remarkably, the chlorine at the 7-position was substituted by a 
bipyrrolidine moiety in DMF at high temperature, while the 
chlorine on the pyridine ring was substituted in the next step by 
excess dimethylamine in THF at room temperature to yield 
compound 94.[22]  
 
Besides phosphorous oxychloride or polyphosphoric acid, an acyl 
chloride such as benzoyl chloride can also effectuate ring closure. 
Refluxing acetyluramil 95 in benzoyl chloride delivered 2-
phenyloxazolo[5,4-d]pyrimidine-5,7-dione 96 (Scheme 18). The 
presence of the phenyl group indicates that transacylation must 
have occurred. The acetyl group on acetyluramil is not very stable, 
and hydrolytic cleavage followed by benzoylation probably 
preceded the cyclization reaction.[23] 
 
Ring closure was also established thermally, without the use of 
any reagent. Pyrimidine 97, with an acetylated amino group at the 
5-position and a hydroxyl group at the 4- and 6-positions, was ring 
closed without any condensing agent by making use of a 
sublimation apparatus at high temperature. The desired 5-amino-
2-methyl-6H-oxazolo[5,4-d]pyrimidin-7-one 98 (8-methyl-9-
oxoguanine) was obtained in very low yield.[24] 
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Scheme 16. Application of the phosphorous oxychloride induced cyclization of 5-acylamino-4-hydroxypyrimidines as reported by Olsson and 
coworkers.[21] 
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Scheme 17. Cyclization of 5-acylamino-4-hydroxypyrimidines utilizing polyphosphoric acid. 
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Scheme 18. Cyclization of 5-acylamino-4-hydroxypyrimidines under 
forcing conditions. 
3.1.3. Starting from a 5-(acyl)amino-4(,6)-
(di)chloropyrimidine 
Another suitable building block is a 5-aminopyrimidine with a 
chlorine atom on the 4- and/or 6-positions. The amino group can 
either be free or acylated (Scheme 19).  
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Scheme 19. Oxazolo[5,4-d]pyrimidines by annulation of oxazole rings to 
5-amino-4-chloropyrimidines. 
Treatment of 4-chloro-5-aminopyrimidine 99 with equimolar 
amounts of benzoic acid and PPA in phosphorous oxychloride 
under reflux conditions afforded oxazolopyrimidine 109 in good 
yield (Scheme 20).[25] Similarly, treatment of 5-amino-2,4-
dichloropyrimidine 101 with arylcarboxylic acids in refluxing POCl3 
gave 5-chlorooxazolo[5,4-d]pyrimidines 110 in very good 
yields.[26] 5-Amino-4,6-dichloropyrimidine 103 was treated with 
benzoyl chloride to obtain 7-chlorooxazolo[5,4-d]pyrimidine 111 
in good yield.[27] Cyclization of acylated 5-amino-4,6-
dichloropyrimidine 112 did not require phosphorous oxychloride 
or polyphosphoric acid and treatment with a simple inorganic base 
such as cesium carbonate in acetonitrile was sufficient to get the 
7-chlorooxazolo[5,4-d]pyrimidine 113 in acceptable yield. 
Subsequent substitution of the chlorine with an appropriate amine 
afforded the 2,7-disubstituted oxazolopyrimidine 114.[28]  
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Scheme 20. Cyclizations of 5-acylamino-4-chloropyrimidines under 
forcing conditions. 
A facile synthesis of 2,5,7-trisubstituted oxazolo[5,4-d]pyrimidines 
108 was developed by Xu et al. (Scheme 21). A combination of 
copper (I) and dimethylethylenediamine as ligand was used to 
catalyze the intramolecular C-O cross-coupling of the ortho-
halopyrimidine amides 107 to provide the oxazolopyrimidines 108 
in moderate to very good yields.[29]  
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Scheme 21. Cyclization of 5-acylamino-4-hydroxypyrimidines by means of 
copper catalysis. 
 
3.1.4. Cyclization of a 4-hydroxy-5-
thioureidopyrimidine  
Analogous to the 5-acylamino-4-hydroxypyrimidines, 4-hydroxy-
5-thioureidopyrimidines can be cyclized to oxazolo[5,4-
d]pyrimidines (Scheme 22).  
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Scheme 22. Oxazolo[5,4-d]pyrimidines by cyclization of 4-hydroxy-5-
thioureidopyrimidines. 
Pyrimidinone 119 was first reacted with methoxycarbonyl 
isothiocyanate to afford the thioureido intermediate 120 in 
moderate yield (Scheme 23). Ring closure was then effectuated 
by treatment with dicyclohexylcarbodiimide to get 
oxazolopyrimidines 121 in very good yields.[30] 
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Scheme 23. DCC induced cyclization of 4-hydroxy-5-
thioureidopyrimidines as reported by Townsend and coworkers.[30] 
When 5-aminopyrimidin-4-ol 122 was treated with O-phenyl 
chlorothionoformate, an intermediate O-thiocarbamate 123 was 
formed (Scheme 24). This crude product was then reacted with a 
highly functionalized pyrrolidine to get thioureidopyrimidine 
structure 124 in very low yield. The oxazole ring cyclization was 
effectuated by treatment with silver nitrate and aqueous 
ammonium hydroxide in ethanol to afford the intermediate 2-
substituted oxazolo[5,4-d]pyrimidine 125. This crude product was 
then deprotected by stirring in a mixture of trifluoroacetic acid and 
dichloromethane, followed by stirring in a mixture of 
ethylenediamine and methanol to obtain 126.[31]  
3.2. Scaffold construction starting from a functionalized 
oxazole 
A second synthetic pathway towards oxazolo[5,4-d]pyrimidines is 
the annulation of a pyrimidine ring on a functionalized oxazole. 
The oxazole usually has a free amino group at the 5-position and 
a nitrile, ester or amide group at the 4-position.  
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Scheme 24. Silver nitrate induced cyclization of 4-hydroxy-5-thioureidopyrimidines as reported by Glenn and coworkers.[31] 
3.2.1. Starting from a 5-aminooxazole-4-carbonitrile 
A C(2)-functionalized 5-aminooxazole-4-carbonitrile is a versatile 
building block for the construction of different oxazolo[5,4-
d]pyrimidines (Scheme 25). 
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Scheme 25. Oxazolo[5,4-d]pyrimidines by annulation of pyrimidine rings 
to 5-aminooxazole-4-carbonitriles. 
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Reaction of 4-cyano-5-aminooxazole 127a with formamidine 
acetate delivered 7-aminooxazolo[5,4-d]pyrimidine 128a 
(Scheme 26). The low yield was attributed to facile ring opening 
and degradation of the 5-amino-4-cyanooxazole.[32] Substitution 
of the 2-position of the oxazole with a 2-furanoyl or phenyl 
substituent improved the stability and accordingly products 128b-
c were obtained in higher yields.[17,33] Reaction of 136 with urea at 
high temperature gave 7-aminooxazolopyrimidin-5-ol 137, while 
treatment with a mixture of formic acid and acetic anhydride at 
80 °C afforded oxazolopyrimidin-7-one 138.[33] Diphosgene was 
also applied in the direct ring closure of 5-aminooxazole-4-
carbonitrile 139, affording the 5,7-dichlorooxazolopyrimidine 140 
in low yield. Subsequent substitution of the 7- and 5-position with 
appropriate amines resulted in compound 142.[34] 
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Scheme 26. One-step condensation of 4-cyano-5-aminooxazoles with a 
variety of one-carbon synthons. 
Pyrimidine ring annulation was also achieved in two steps. 
Reaction of oxazole 127 with an orthoester in refluxing acetic 
anhydride afforded the intermediate N-ethoxymethylene 
derivatives 132 in moderate to excellent yields (Scheme 27). Ring 
closure with aqueous ammonia then afforded the desired 7-
aminooxazolo[5,4-d]pyrimidines 133.[35] Instead of aqueous 
ammonia, aqueous solutions of various primary amines in water 
could also be used to obtain a substituted 7-amino group on this 
scaffold.[36] Reaction of oxazole 136 with N,N-dimethylformamide 
dimethyl acetal in NMP resulted in amidine 143 in very good yield. 
Subsequent cyclization by treatment with various anilines in 
acetic acid gave N-substituted oxazolopyrimidin-7-amines 144 in 
varying yields.[33] 
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Scheme 27. Two-step condensation of 4-cyano-5-aminooxazoles with acetic anhydride or N,N-dimethylformamide dimethyl acetal. 
3.2.2. Starting from various other 2,4,5-trisubstituted 
oxazoles 
A variety of other 2,4,5-trisubstituted oxazoles were applied as 
building blocks for the construction of oxazolo[5,4-d]pyrimidines 
(Scheme 28). 
 
Formylated 5-aminooxazole 145 was cyclized to oxazolo[5,4-
d]pyrimidine-7-ols 146 in very low yield by treatment with a boiling 
potassium bicarbonate solution (Scheme 29).[37] When ethyl 5-
aminooxazole-4-carboxylates 156 were treated with benzoyl 
isothiocyanate, thioureas 147 were obtained in moderate yields. 
Direct cyclization of these thiourea structures towards the 5-
aminooxazolo[5,4-d]pyrimidin-7(6H)-ones 148 with ammonia in 
methanol was unsuccessful. This cyclization was achieved in low 
yields by a step-wise methylation, followed by cyclization in the 
presence of ammonia in methanol. Alternatively, thioureas 147 
were ring closed to 5-mercaptooxazolo[5,4-d]pyrimidin-7(6H)-
ones 149 by aqueous potassium hydroxide in ethanol in good 
yields.[38] Ethyl 5-aminooxazole-4-carboxylate 156 was also used 
to construct oxazolo[5,4-d]pyrimidinones 187 through a 
consecutive aza-Wittig reaction. Treatment with 
triphenylphosphine, hexachloroethane and triethylamine 
produced iminophosphorane 184 in good yield. Further reaction 
with isocyanates afforded the carbodiimide intermediates 185, 
which reacted smoothly with secondary amines to generate 
guanidines 186. Ring closure to the desired oxazolopyrimidinones 
187 was effectuated by a catalytic amount of sodium ethoxide in 
good overall yields.[39]  
 
In the same study on protein kinase B (PKB) inhibitors as 
mentioned in section 2.2 on oxazole[4,5-d]pyrimidines, two new 
C(2)/C(4)-functionalized oxazolo[5,4-d]pyrimidines 159 were 
synthesized (Scheme 30). Unfortunately, the synthesis and 
characterization of these compounds was not described in detail. 
The only structures of Scheme 30 which were unambiguously 
reported are the final structures 159. According to a general  
 
 
reaction scheme, the starting material was 5-aminooxazole 150 
with an ester group at the 4-position and optionally a substituent 
at the 2-position. This oxazole was cyclized to afford oxazolo[5,4-
d]pyrimidin-5,7(4H,6H)-dione 151. Chlorination of this compound 
then lead to 5,7-dichloropyrimidine 157, which was subsequently 
substituted at the 7- and 5-position to obtain the final structures 
159. No biological results were reported.[8] 
 
All of the aforementioned reactions require heating of the reaction 
mixture, which may be undesirable when fragile substituents are 
involved. Therefore, Kornienko and coworkers developed a 
method to construct functionalized oxazolopyrimidines under mild 
reaction conditions. Reacting 4-cyanooxazole-5-sulfonyl 
chlorides 152 with various amidines at room temperature in THF 
afforded the desired oxazolopyrimidines 153 in moderate yields 
(Scheme 31).[40,41]  
 
The Cornforth rearrangement is a reaction which is specific for 4-
acyloxazoles. This rearrangement was used to develop a new 
synthetic pathway towards oxazolo[5,4-d]pyrimidin-7-ones 163 
(Scheme 32). Reaction of 4-acyloxazole 160 with an appropriate 
amidine delivered the intermediate acylamidines 161 in good 
yields. Thermolysis in refluxing toluene induced the Cornforth 
rearrangement reaction and gave the amidines 162 in good to 
excellent yields. These were subsequently cyclized to 
oxazolopyrimidin-7-ones 163 by treatment with ethanolic 
potassium hydroxide in very good yields.[42] 
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Scheme 28. Oxazolo[5,4-d]pyrimidines by annulation of pyrimidine rings to oxazoles with appropriate substituents at positions 4 and 5. 
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Scheme 29. Annulation of pyrimidine rings to 4-carboxy-5-aminooxazoles using a variety of one-carbon synthons. 
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Scheme 30. Application of the annulation of pyrimidine rings to 4-carboxy-
5-aminooxazoles as reported by Wymann and coworkers.[8] 
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Scheme 31. Annulation of pyrimidine rings to 4-cyanooxazole-5-sulfonyl 
chlorides as reported by Kornienko and coworkers.[40,41] 
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Scheme 32 Synthesis of oxazolo[5,4-d]pyrimidin-7-ones through the 
Cornforth rearrangement, as reported by Maryanoff and coworkers.[42] 
3.3. Scaffold construction starting from violuric acid  
Violuric acid (164) can be converted to 2-substituted oxazolo[5,4-
d]pyrimidine-5,7(4H,6H)-diones by reaction with 
triphenylphosphonium salts or triphenylphosphonium ylides 
(Scheme 33). Thus, treating violuric acid with various 
triphenylphosphonium bromides and aqueous lithium hydroxide 
in ethanol afforded the oxazolopyrimidine-5,7-diones 165 in 
moderate to good yields. No reaction occurred when ester 
triphenylphosphonium bromides were used, while the 
corresponding ester ylides delivered the 2-carboxylated 
oxazolopyrimidinones 166 in low yields.[43]  
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Scheme 33. Synthesis of oxazolo[5,4-d]pyrimidine-5,7(4H,6H)-diones 
through the condensation of violuric acid and Wittig reagents, as reported 
by Barghash and coworkers.[43] 
3.4. Biological activity 
3.4.1. Receptor modulators 
Compound 51 (Figure 2, Scheme 12) is an in vitro P2Y1 receptor 
antagonist with a Ki value of 24 nM. The P2Y1 receptor is an 
important receptor for ADP in platelets. In turn, platelet activation 
is known to play a pivotal role in thrombus formation. Therefore, 
P2Y1 antagonists could have significant utility in the treatment of 
a variety of thrombotic disorders. Compound 51 inhibits ADP-
induced platelet aggregation with an IC50 value of 3.9 µM.[44] 
 
Structure 80 (Figure 2, Scheme 15) is an A2 adenosine receptor 
antagonist with an IC50 value below 100 nM. This receptor plays 
an important role in the regulation of glutamate and dopamine 
release, and could be useful in treatment of conditions such as 
pain, insomnia, depression, drug addiction and Parkinson’s 
disease.[17] Structure 80 was used as a lead compound in a later 
study on the development of selective A2A adenosine receptor 
antagonists for positron emission tomography (PET). This 
resulted in compounds 88 (Scheme 16). Compounds 88 are 
inhibitors of the A2A adenosine receptor (A2AAR) with IC50 values 
ranging from 14-33 nM and of the A1 adenosine receptor (A1AR) 
with IC50 values ranging from 170-1700 nM, resulting in A2A/A1 
selectivity ratios ranging from 5 to 91. However, a high degree of 
unspecific binding was observed in vitro, rendering these 
compounds useless as PET ligands.[21] 
 
Molecule 167 (Figure 2) is an angiotensin II receptor antagonist 
with an IC50 value of 98 nM. This receptor belongs to the class of 
GPCRs and is responsible for the signal transduction of the 
vasoconstricting stimulus of the peptide hormone angiotensin II. 
Antagonists of this receptor can be useful in the control of 
hypertension and related illnesses.[45] 
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Compound 114 (Figure 2, Scheme 20) is an in vitro antagonist of 
the human transient receptor potential protein vanilloid receptor 1 
(TRPV1) with an IC50 value of 136 nM. TRPV1 antagonists may 
be useful in disorders or conditions mediated by TRPV1 activity, 
such as pain, itch, arthritis, cough, asthma or inflammatory bowel 
disease.[28] 
 
Structure 168 (Figure 2, Scheme 21) is an inhibitor of the vascular 
endothelial growth factor receptor 2 (VEGFR-2) with an IC50 value 
of 0.33 µM. The vascular endothelial growth factor is a key 
mediator of angiogenesis, which is a critical process in solid tumor 
progression. 168 possesses antiproliferative activity against 
HepG2 and U251 cells with IC50 values of 15.5 and 15.3 µM, 
respectively, and was active against VEGF-induced human 
umbilical vein endothelial cell (HUVEC) proliferation with an IC50 
value of 0.29 µM.[46] Compound 169 (Figure 2) is an inhibitor of 
VEGFR-2 with an IC50 value of 0.3 µM. However, it was not 
selective and also inhibits EGFR with an IC50 value of 0.2 µM.[47] 
 
Molecule 170 (Figure 2) is an agonist of the endothelial 
differentiation gene receptor 1 (EDG-1) and was three times more 
active than the positive control substance sphingosine 1-
phosphate at 10 µM.[20] Further work lead to compound 171 
(Figure 2), an EDG-1 agonist which effectively reduced the 
severity of acute kidney disease (AKI) in a murine in vivo model.[48] 
3.4.2. Kinase inhibitors 
The 2,7-disubstituted oxazolo[5,4-d]pyrimidine 94 (Figure 3, 
Scheme 17) is an inhibitor of adenosine kinase (AK) with an IC50 
value of 10 nM. AK inhibition is an attractive therapeutic approach 
for several conditions such as neurodegeneration, seizures, 
ischemia, pain and inflammation.[22] Compounds 172a-b (Figure 
3) inhibit AK with Ki values of 11.1 and 25.2 µM, respectively. The 
latter also showed selectivity for adenosine A1 over A2A 
receptors.[49] 
 
Compounds 173 (Figure 3) are in vitro inhibitors of Aurora A 
kinase with IC50 values between 1 and 50 nM. Aurora kinases 
belong to the serine/threonine subclass of kinases and are 
involved in the regulation of mitosis. The derivative with a 4-pyridyl 
substituent at the 2-position was active against HCT-116 cancer 
cells in vitro with a cytotoxicity IC50 value lower than 100 nM.[50] 
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Figure 2. Oxazolo[5,4-d]pyrimidines reported as receptor modulators. 
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Structure 126 (Figure 3, Scheme 24) is a JAK1 inhibitor with an 
IC50 value between 50 and 100 nM. JAK1 is a tyrosine kinase and 
plays an important role in initiating responses to cytokine 
receptors. Expression of JAK1 in cancer cells is related to 
metastasis.[31] Compound 142 (Figure 3, Scheme 26) is an in vitro 
inhibitor of JAK2 kinase with an IC50 value of 2.3 µM. Remarkably, 
its thiazolo[5,4-d]pyrimidine analogue, with a sulfur atom in 
structure 142 instead of an oxygen atom, has an IC50 value of 3 
nM.[34] 
3.4.3. Miscellaneous biological activity 
Compound 98 (Figure 4, Scheme 18) is an effective inhibitor of 
ricin toxin A chain (RTA) with an IC50 value of 0.40 mM.[24] It was 
also found to be an effective inhibitor of Shiga toxin 1 A1 (Stx1A1) 
with an IC50 value of 2 mM.[51] Ricin is a highly toxic lectin (a 
carbohydrate-binding protein) which naturally occurs in the seeds 
of the castor oil plant, Ricinus communis. The Shiga toxin is 
produced by Shigella dysenteriae and shigatoxigenic serotypes of 
Escherichia coli. The structurally similar purine isosteres 174 
(Figure 4) are competitive inhibitors of human erythrocytic 
hypoxanthine-guanine phosphoribosyl transferase (HGPRT) with 
Ki values ranging from 84 to 173 µM. HGPRT plays a central role 
in the generation of purine nucleotides through the purine salvage 
pathway. Inhibitors of HGPRT could be useful to treat 
schistosomiasis and malaria, diseases in which the parasites lack 
the de novo purine biosynthetic pathway.[52] 
 
Nucleoside analogues 6-(β-D-ribofuranosyl)oxazolo[5,4-
d]pyrimidin-7-ones 175 (Figure 4) were prepared by a standard 
glycosylation reaction on trimethylsilylated 2-substituted 
oxazolo[5,4-d]pyrimidin-7-ones. The less bulky nucleoside 
analogues (R = Me, Et, n-Pr) inhibit the proliferation of leukemia 
L1210 cells with IC50 values between 7 and 50 µM while the more 
bulky (R = i-Pr, Ph) derivatives had IC50 values higher than 100 
µM. They also inhibit the proliferation of E. coli K12 cells with IC50 
values between 0.5 and 6 µM for the n-propyl and ethyl group 
respectively, while for methyl and the bulky substituents, IC50 
values higher than 100 µM were observed.[53]  
 
Structure 176 (Figure 4) is an inhibitor of the NEDD8-activating 
enzyme (NAE) with an IC50 value below 500 nM. Activated 
NEDD8 is needed in two DNA repair pathways. NAE inhibition 
may cause deficient DNA repair leading to accumulation of DNA 
damages, eventually resulting in cell death. Cancer cells may be 
more sensitive to this effect compared to normal cells if the cancer 
cells are independently deficient in DNA repair.[27]  
 
Molecule 177 (Figure 4) is an activator of the caspase cascade in 
different cancer cell lines with EC50 values between 58-93 nM. 
Caspases are a family of protease enzymes that play essential 
roles in programmed cell death and inflammation.[11]  
 
Compound 178 (Figure 4) is an in vitro inhibitor of plasma 
kallikrein (PK) with an IC50 value of 1.78 µM. PK is the activated 
form of the trypsin-like serine protease plasma-prokalliokrein and 
is mainly expressed by hepatocytes in the liver. PK inhibitors are 
considered to be useful in the treatment of a wide range of 
disorders, in particular retinopathy or edema-associated diseases, 
such as hereditary angioedema, macular edema and brain 
edema.[54]  
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Figure 3. Oxazolo[5,4-d]pyrimidines reported as kinase inhibitors. 
10.1002/ejoc.201800133
Ac
ce
pt
ed
 M
an
us
cr
ip
t
European Journal of Organic Chemistry
This article is protected by copyright. All rights reserved.
MICROREVIEW          
 
 
 
 
 
HN
NH2N O
O
N
Me
98
Ricin and Shiga toxin inhibitor
Research Development Foundation
(2001)
N
N
OH
N
O
R
174
R = Me, Et, 
n-Bu, Ph
HGPRT inhibitor
Academic
(1979)
N
N
O
N
R
OO
OHOH
HO
175
R = Me, Et, n-Pr, 
i-Pr, n-Bu, Ph
Antiproliferative agent
Academic
(1974)
N
N
N
O
Ph
HN
OH
O S
O
O
NH2
176
NAE inhibitor
Millennium Pharmaceuticals
(2008)
N
N
N
N
O
Me
Me
Me
MeO
177
Caspase cascade activator
Cytovia
(2008)
N
N
NH
N
O
N
MeMe
Me
Cl
Cl
178
Plasma kallikrein inhibitor
Novartis
(2014)
N
N N
O
Ph
N
Me
NHAc
179
Acetyl-CoA carboxylase 2 inhibitor
Boehringer Ingelheim
(2013)
N
ON
N
N
H2N
F
N
O
O
180
Cl
Immunosuppressant
Academic
(2011)
N
NMe
N
O
OMe
HN
H
N
O
Cl
181
N
N N
OMe
HN
H
N
H
N
O
F
Cl
O
N N Me
182
N
N N
O
Me
N
N N
N
N
N
O
183
Anti-angiogenic agent
Academic
(2015)
Anti-angiogenic agent
Academic
(2016)
Antiviral agent
Janssen Sciences Ireland
(2016)
 
Figure 4. Oxazolo[5,4-d]pyrimidines of assorted biological interest.  
Compound 179 (Figure 4) inhibits acetyl-CoA carboxylase 2 
(ACC2) in vitro with an IC50 value of 0.34 µM. ACC2 is one of the 
two isoforms of ACC in mammals, and regulates the metabolism 
of fatty acids. Inhibitors of ACC2 could be useful in the treatment 
of obesity and diabetes.[55]  
 
Compound 180 (Figure 4) is an immunosuppressing agent and 
inhibits the in vitro Mixed Lymphocyte Reaction (MLR) test with 
an IC50 value of 3 µM.[56] This type of structures also possesses 
antiviral activity against poliovirus and hepatitis C genotype 1a 
(HCV-1a).[57]  
Compound 181 (Figure 4) inhibits human umbilical vein 
endothelial cell (HUVEC) proliferation in vitro with an IC50 value of 
9.3 µM and possesses superior anti-angiogenic activity.[58] 
Further research by the same group lead to a similar compound, 
182 (Figure 4), which also possesses anti-angiogenic activity and 
inhibits HUVEC proliferation in vitro with an IC50 value of 12.4 µM. 
Despite the higher IC50 value, compound 182 had a better dose-
response curve than compound 181 and was preferred for further 
study.[59]  
Compound 183 (Figure 4) is an antiviral compound with activity 
against respiratory syncytial virus (RSV) and inhibits replication of 
the rgRSV224 virus in vitro.[60] 
4. Conclusions  
The available methodology to construct oxazolo[4,5-d]pyrimidines 
and oxazolo[5,4-d]pyrimidines, as published in primary scientific 
literature and patents up to the end of 2017, was summarized in 
this work. 
 
A significant body of research has been published on oxazolo[5,4-
d]pyrimidines. An array of synthetic pathways is available to 
access diversely decorated members of this chemical family. 
Most approaches start from a functionalized pyrimidine or oxazole. 
Oxazolo[5,4-d]pyrimidines have been subjected to many 
biological studies. Significant activity has been reported in more 
than twenty instances, varying from a receptor (ant)agonist profile 
to the inhibition of proliferation and specific enzymes such as 
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kinases. An important number of patent applications covering 
these findings have accordingly been filed in recent years. 
Relevant clinical settings were predominantly situated in oncology 
and infectious diseases. 
 
Oxazolo[4,5-d]pyrimidines on the contrary represent an 
underexplored class of compounds. Limited access to this 
scaffold has led to an according lack of biological studies. Current 
synthetic methods are mostly confined to oxazole ring annulation 
on a functionalized pyrimidine or pyrimidine ring annulation on a 
functionalized oxazole. We hope that this literature overview will 
stimulate the exploration of new synthetic avenues towards 
oxazolo[4,5-d]pyrimidines. Of particular value would be the 
development of a versatile building block such as 5,7-
dichlorooxazolo[4,5-d]pyrimidine or its chemical equivalent. 
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